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Summary
Background There is ongoing debate on the clinical benefits of antibiotic prophylaxis for reducing pelvic infection after 
miscarriage surgery. We aimed to study the cost-effectiveness of antibiotic prophylaxis in the surgical management of 
miscarriage in low-income countries.
Methods We did an incremental cost-effectiveness analysis using data from 3412 women recruited to the AIMS trial, 
a randomised, double-blind, placebo-controlled trial designed to evaluate the effectiveness of antibiotic prophylaxis in 
the surgical management of miscarriage in Malawi, Pakistan, Tanzania, and Uganda. Economic evaluation was done 
from a health-care-provider perspective on the basis of the outcome of cost per pelvic infection avoided within 2 weeks 
of surgery. Pelvic infection was broadly defined by the presence of clinical features or the clinically identified need to 
administer antibiotics. We used non-parametric bootstrapping and multilevel random effects models to estimate 
incremental mean costs and outcomes. Decision uncertainty was shown via cost-effectiveness acceptability frontiers. 
The AIMS trial is registered with the ISRCTN registry, number ISRCTN97143849.
Findings Between June 2, 2014, and April 26, 2017, 3412 women were assigned to receive either antibiotic prophylaxis 
(1705 [50%] of 3412) or placebo (1707 [50%] of 3412) in the AIMS trial. 158 (5%) of 3412 women developed pelvic 
infection within 2 weeks of surgery, of whom 68 (43%) were in the antibiotic prophylaxis group and 90 (57%) in the 
placebo group. There is 97–98% probability that antibiotic prophylaxis is a cost-effective intervention at expected 
thresholds of willingness-to-pay per additional pelvic infection avoided. In terms of post-surgery antibiotics, the 
antibiotic prophylaxis group was US$0·27 (95% CI –0·49 to –0·05) less expensive per woman than the placebo 
group. A secondary analysis, a sensitivity analysis, and all subgroup analyses supported these findings. Antibiotic 
prophylaxis, if implemented routinely before miscarriage surgery, could translate to an annual total cost saving of up 
to $1·4 million across the four participating countries and up to $8·5 million across the two regions of sub-Saharan 
Africa and south Asia.
Interpretation Antibiotic prophylaxis is more effective and less expensive than no antibiotic prophylaxis. Policy 
makers in various settings should be confident that antibiotic prophylaxis in miscarriage surgery is cost-effective.
Funding UK Medical Research Council, Wellcome Trust, and the UK Department for International Development.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Globally, about 210 million pregnancies are estimated to 
occur annually, 90% of which are in low-income countries.1 
Almost 84 million (40%) of these pregnancies end in 
either miscarriage or induced abortion, in about equal 
proportions.2,3 National and international guidelines on 
the surgical management of induced abortion advocate 
the use of antibiotic prophylaxis to reduce the risk of 
infection.4–6 These guidelines are underpinned by strong 
evidence on the clinical effectiveness of prophylactic 
antibiotics given before surgical abortion.7
By contrast, sufficient evidence to support the routine 
use of antibiotic prophylaxis in the surgical management 
of miscarriage is scarce,8 and current guidelines do not 
recommend the use of antibiotics before miscarriage 
surgery, unless there is evidence of infection.9 Surgical 
removal of miscarriage tissues is a most common method 
of miscarriage management,10 particularly in low-income 
countries where it represents up to 70% of all gynae-
cological admissions.11 Infection is a serious complication 
of miscarriage surgery and occurs in up to 30% of women 
in low-income countries,12 with potentially signifi cant mor-
bidity and mortality implications.13,14 There is an urgent 
need for a more comprehensive evaluation of the potential 
role of antibiotic prophylaxis in this context,8 which has the 
potential to offer significant clinical and economic benefits 
to health systems globally.
In response to this, the Antibiotics In Miscarriage 
Surgery (AIMS) trial was jointly funded by the UK 
Medical Research Council, the Wellcome Trust, and the 
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UK Department for International Development, as part 
of the Joint Global Health Trials Scheme, to evaluate the 
effectiveness of antibiotic prophylaxis during the surgical 
management of miscarriage in low-income countries. 
Here, we use data from the AIMS trial to determine 
the relative cost-effectiveness of antibiotic prophylaxis 
compared with placebo in the surgical management 
of miscarriage based on the outcome of cost per pelvic 
infection avoided within 2 weeks of surgery.
Methods
Study design and participants
The AIMS trial was a multinational randomised, double-
blind, placebo-controlled trial. Detailed information 
about the trial design and participants can be found in 
the published trial protocol15 and the clinical paper.16 
Briefly, 3412 women with a spontaneous miscarriage 
(<22 weeks’ gestation) undergoing surgical management 
of mis carriage with manual vacuum aspiration, suction 
curett age, or sharp curettage, and who were willing and 
able to provide informed consent, were recruited across 
13 hospitals in Malawi, Pakistan, Tanzania, and Uganda 
between June, 2013, and April, 2017. Women were 
excluded from the study if they were younger than 
16 years or had induced abortion of pregnancy, septic 
miscarriage or evidence of infection, allergy to 
prophylactic antibiotics (ie, doxycycline or metronidazole), 
used antibiotics within 7 days before randomisation, 
febrile illness, other con traindication to doxycycline and 
metronidazole, or a condition requiring immediate care, 
such as severe haem orrhage. Women were randomly 
assigned (1:1), using a secure internet facility, to receive a 
single preoperative dose (about 2 hours before surgery) 
of doxycycline (400 mg oral) and metronidazole (400 mg 
oral) or identical placebos. Although obesity is a key 
factor in the choice of dosage of prophylactic antibiotics 
in high-income countries, obesity was not an issue in the 
AIMS trial and, therefore, it was not formally considered. 
Women were asked to attend an in-person follow-up 
assessment on day 14 after treatment. No further formal 
assessment was made in participants who attended for 
this day 14 assessment. Those who did not attend were 
prompted by telephone (to themselves or their nominated 
contact person) to attend at a time convenient for them, 
or were offered in-person visits to their home address to 
minimise loss to follow-up. These additional attempts to 
contact those who did not attend for follow-up were 
permitted until day 28. Ethics approval was granted from 
the Liverpool School of Tropical Medicine Research 
Ethics Committee in the UK, the College of Medicine 
Research and Ethics Committee in Malawi, the National 
Council for Science and Technology in Uganda, the 
Ifakara Health Institute in Tanzania, and the Aga Khan 
University in Pakistan.
Effectiveness outcome
The outcome of the AIMS trial was pelvic infections 
avoided within 2 weeks of surgery. As per trial protocol, 
pelvic infection was determined in the presence of two or 
more of the following clinical features: purulent vaginal 
discharge, pyrexia (>38°C), uterine tenderness on 
examination, and white cell count of more than 12 × 10⁹ 
cells per L, with no other recognised cause of infection, or 
only one of these four clinical features if there was a 
clinically identified need to administer antibiotics for the 
treatment of a presumed pelvic infection.
Resource use and costs
Resource use information was collected prospectively 
via case report forms. Forms were completed on at least 
one occasion before discharge after surgery, at every 
contact assessment during the follow-up period, daily 
whilst an inpatient, and at final assess ment. Resource 
use information was collected from the perspective of 
Research in context
Evidence before the study
 In low-income countries, the surgical removal of miscarriage 
tissues is the most common method of miscarriage management. 
To date, national and international guidelines on the surgical 
management of miscarriage do not recommend the use of 
prophylactic antibiotics to reduce the risk of pelvic infection. 
Infections after miscarriage surgery are frequent in low-income 
settings and have been associated with clinically significant 
morbidity and mortality implications. A Cochrane review showed 
no previous high quality evidence of effectiveness, with four small 
single-centered studies showing no significant benefit from 
prophylactic antibiotics. The AIMS trial provided evidence on the 
role of antibiotic prophylaxis in miscarriage surgery.
Added value of this study
To our knowledge, this study is the first to assess the 
cost-effectiveness of antibiotic prophylaxis relative to placebo 
in women undergoing surgical management of miscarriage 
in low-income settings. We find that antibiotic prophylaxis in 
the surgical management of miscarriage is cost-effective and 
provides substantial economic and health benefits. 
Implications of all the available evidence
For clinicians and policy makers there is now evidence of both 
clinical and cost-effectiveness. Our interpretation is that this 
new evidence should result in the recommendation that, in 
low-resource settings, antibiotic prophylaxis should be 
administered before miscarriage surgery. Guidelines on the 
management of miscarriage should be updated on the basis of 
this evidence.
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the health-care provider and included anti biotics and 
medications related to pain, allergy, diarrhoea, vomiting, 
nausea, malaria, and fever as well as inpatient hospital 
stays, outpatient visits, laboratory examina tions, and 
treatment of complications for which antibiotic prophy-
laxis could potentially offer a clinical benefit. Such 
complications were haemorrhage requiring blood trans-
fus ion, repeat uterine evacuation, and ana phylaxis. 
Other rare complications, such as uterine perforations, 
were not considered as they do not relate to antibiotic 
prophylaxis and were expected to equally appear in both 
groups of the trial.
We calculated the cost associated with the use of 
antibiotics and other commonly prescribed medications 
on the basis of established dosage regimens and patient-
specific duration of treatment. Mean unit costs were 
obtained from the International Drug Price Indicator 
Guide,17 which is recommended as the principal source 
for medication costs in low-income and middle-income 
settings.18 An adjustment of 25% was used to account 
for shipping, handling, and internal distribution costs 
(table 1).18,19 Country-specific and hospital-specific unit 
cost estimates for secondary and tertiary patient services 
in each participating country were obtained from the 
WHO-CHOICE initiative.20 We used other secondary 
sources to estimate the cost of laboratory examinations 
and treatment of relevant complications.21–25 For women 
requiring blood transfusion, we used unit cost estimates 
for hospital-based blood transfusion services.22,23 Appro-
priate cost estimates for repeat surgical removal of 
pregnancy tissues were used according to whether the 
surgery was done using dilatation and curettage or 
manual vacuum aspira tion.24,25 All non-medication-related 
unit costs used in the analysis are shown in table 2.
To standardise unit costs across countries in cases where 
data were not available, an index table was used to indicate 
the relative mean cost of tertiary and secondary inpatient 
and outpatient hospital services for each country-pair 
in the study, based on the WHO-CHOICE estimates 
(appendix p 1). This market-basket approach was used in 
the Disease Control Priorities Project that aimed to inform 
disease control priorities in low-income countries using 
economic evaluation,18 and it is an established costing 
method for the development of a complete set of country-
specific unit cost data in multinational trials.26 All 
unit costs were adjusted to 2016 US$ using the average 
US inflation rate between the price base year used in 
individual studies and 2016, as recom mended when there 
is a relatively high proportion of imported commodities 
in economic analyses.27 Given that the follow-up period 
was 2 weeks, costs were not discounted.
Statistical analysis
Evidence suggests that health-care service provision and 
patient outcomes differ across different hospitals within 
one country and across countries,28 with these differences 
being particularly profound in low-income settings. 
Thus, owing to the multinational nature of the AIMS 
trial and the differences identified in costs and clinical 
outcomes across countries and hospitals, we used a 
multilevel random effects model to estimate the 
differences in mean costs and outcomes between the 
antibiotic prophylaxis and placebo trial groups. Multilevel 
modelling accounts for unobserved hospital-specific and 
country-specific effects on costs and outcomes and allows 
for the estimation of cost-effectiveness across the whole 
sample and for the individual participating countries.29
We did an incremental cost-effectiveness analysis to 
compare the costs and outcomes associated with the 
two groups of the trial. To account for the inherent 
uncertainty around cost-effectiveness point estimates, 
we used non-parametric bootstrapping with multilevel 
models to generate 1000 paired estimates of incremental 
mean costs and outcomes adjusted for age, marital 
See Online for appendix
Unit cost
Antibiotic prophylaxis $0·091
Pain  
Mild $0·049
Moderate $0·093
Severe $0·835
Allergy
Mild $0·010
Moderate $0·103 
Severe $1·614
Diarrhoea
Mild $0·551 
Moderate $3·849
Severe $5·361
Vomiting
Mild $0·036 
Moderate $0·641
Severe $5·239
Fever*
Mild $0·049
Moderate $0·049
Severe $0·049
Nausea
Mild $0·036 
Moderate $0·855
Severe $1·768
Malaria
Mild $0·434 
Moderate $1·713
Severe $1·980
Infection
Mild $0·063
Moderate to severe $1·693
Source: International Drug Price Indicator Guide (2015).17 *Main treatment is 
reflected on antibiotics use and investigations.
Table 1: Medication-related unit costs by severity (US$, 2016 price base)
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status, gestational age, previous miscarriage or stillbirth, 
evidence of induced abortion, HIV status, type of 
miscarriage surgery, cadre of surgeon (ie, specialist 
doctor, non-specialist doctor, or non-physician, including 
midwives, nurses, and other clinical staff), and residential 
characteristics. We used the bootstrapping results to 
derive cost-effectiveness acceptability frontiers,30 which 
plot the probability of the optimal strategy being cost-
effective across a range of values of willingness-to-pay 
per additional unit of outcome (ie, per pelvic infection 
avoided within 2 weeks of surgery).
The economic evaluation relied on available case 
analysis since only 74 (2%) of 3412 women were 
censored at 2 weeks follow-up. Given that group 
allocation was found to be a predictor of missingness 
in the AIMS trial data (ie, women in the antibiotic 
prophylaxis group were more likely to be missing),16 we 
did an additional multiple imputation analysis under 
the assumption that data were missing not at random. 
Although in this clinical context it was expected that 
censored women did not develop any pelvic infection, 
the analysis was done under the assumption that all 
censored women developed pelvic infection as a worst-
case scenario. The multiple imputation was done using 
chained equations.31 Differences between the antibiotic 
prophylaxis group and placebo in terms of mean costs 
and outcomes from the 10 multiply imputed datasets 
were obtained according to Rubin’s rules,32 using 
multilevel random effects models.33,34
We did subgroup analyses to assess the relative cost-
effectiveness of antibiotic prophylaxis for each part-
icipating country, for the different types of miscarriage 
(incomplete and missed miscarriage), for the different 
types of miscarriage surgery (manual vacuum aspira-
tion, suction curettage, sharp curettage), and for different 
gesta tional age groups (<12 weeks and ≥12 weeks). To 
assess the robustness of the main study findings, we did a 
sensitivity analysis using published regional unit cost 
estimates for each participating country (appendix p 2).18 
We used Stata (version 14.2MP) for all analyses.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between June 2, 2014, and April 26, 2017, 3412 women 
with a median age of 25 years (IQR 18–31) were recruited 
across Malawi (2145 [63%] of 3412), Pakistan (353 [10%]), 
Tanzania (210 [6%]), and Uganda (704 [21%]), and were 
assigned to receive either antibiotic prophylaxis 
(1705 [50%] of 3412) or placebo (1707 [50%] of 3412). Of 
the 3412 women recruited, 2876 (84%) were married, 
2352 (69%) lived in an urban area, and 2086 (61%) were 
unemployed or in a housewife role. In terms of 
residential characteristics, 1060 (31%) women were 
living in rural areas, 589 (17%) had a flushing toilet, and 
772 (23%) had non-shared piped and tapped water. 
1262 (37%) of 3412 reported that they had problems 
getting the food they need sometimes or more often. 
696 (21%) of 3412 women had previously had a 
miscarriage or stillbirth. Further information is available 
in the appendix (p 3).
158 (5%) of 3412 women developed pelvic infection 
within 2 weeks of surgery. Of these women, 68 (43%) 
were in the antibiotic prophylaxis group and 90 (57%) 
in the placebo group. The absolute risk difference be-
tween antibiotic prophylaxis and placebo per woman was 
–1·3% (95% CI –2·8 to 0·2; table 3). The strict defini-
tion of pelvic infection using the clinical criteria only 
(ie, excluding presumed infections in the presence of one 
clinical feature) resulted in a significant difference in the 
risk of pelvic infection between the two groups at the 
5% level (risk ratio 0·60 [95% CI 0·37–0·96]; p=0·03).16 
The clinical findings of the AIMS trial have been 
published in full elsewhere.16
The resource utilisation per group is shown in the 
appendix (p 4). Post-surgery antibiotics prescribed for 
pelvic or other infections, such as urinary tract infection 
and respiratory infection, were the biggest driver of costs, 
accounting for about 50% of the total cost in the two 
groups of the trial (table 3). In terms of post-surgery 
antibiotics, the antibiotic prophylaxis group was US$0·27 
(95% CI 0·05–0·49) less expensive per woman relative to 
the placebo group. This finding is explained by the 
additional days of infection (about 180 days), and possibly 
Malawi Pakistan Tanzania Uganda References
Hospital services*
Inpatient stay
Per day in tertiary hospital $4·41 $13·76 $8·38 $6·58 20
Per day in secondary hospital $3·23 $10·08 $6·13 $4·81 20
Outpatient visit
Per day in tertiary hospital $1·22 $2·64 $2·45 $2·15 20
Per day in secondary hospital $0·83 $1·78 $1·65 $1·45 20
Laboratory examinations
White cell count $1·10 $3·18 $2·10 $1·69 21
Vaginal swab $0·76 $2·19 $1·45 $1·17 21
Blood culture $2·73 $7·89 $5·21 $4·20 21
Urinalysis $1·00 $2·89 $1·91 $1·54 21
Complications
Hospital-based blood transfusion (per unit 
of transfusion-ready blood)
$20·02 $58·45 $21·35 $31·03 22, 40
Repeat evacuation
Dilatation and curettage $18·25 $46·60 $34·81 $28·07 24, 25
Manual vacuum aspiration $3·99 $18·05 $7·61 $6·14 24, 25
*These estimates only show the accommodation component of hospital costs; ie, excluding the cost of drugs 
and diagnostic tests but including personnel, capital, and food costs. 
Table 2: Other resource use categories and associated unit costs (US$, 2016 price base)
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more severe cases of infections, in the placebo group. 
Hospital-services-related costs were the second largest 
driver of costs, accounting for about 20% of the total costs. 
This finding is due to the 150 days of inpatient stay (53% of 
which were in the placebo group) and 164 outpatient visits 
(61% of which were in the placebo group) during the trial. 
The antibiotic prophylaxis group was $0·50 (95% CI 
0·03–1·02) less expensive per woman than the placebo 
group was. In a sensitivity analysis, using the regional 
unit cost, estimates increased the mean per woman cost 
difference to $0·72 (95% CI 0·26–1·69).
The antibiotic prophylaxis group was more effective and 
less expensive than the placebo group was (dominant 
intervention). The figure shows the probability of anti-
biotic prophylaxis being cost-effective across a range of 
willingness-to-pay values per additional pelvic infection 
avoided in the main and secondary analyses. Antibiotic 
prophylaxis has a more than 80% probability of being 
cost-effective for any willingness-to-pay value below 
$20 per pelvic infection avoided (figure). According to 
WHO, for highly cost-effective interventions, decision 
makers should be willing to pay the country’s per capita 
gross domestic product (GDP) for an additional disability-
adjusted life-year (DALY) avoided.35 Other sources recom-
mend that this willingness-to-pay in low-income settings 
should be a maximum of 50% of the per capita GDP.36 
Thus, according to these sources, decision makers in the 
trial context should be willing to pay up to $224 (50% of 
the weighted per capita GDP) or $566 (weighted per capita 
GDP) for one DALY avoided (appendix p 5). Pelvic 
infections have a disability weight of 0·169,37 and are 
known to last up to 2 weeks, which results in 0·0065 DALYs. 
If decision makers are willing to pay $224 or $566 per 
DALY averted, this payment equates to $1·45 or $3·67 for 
0·65% of a DALY. At these willingness-to-pay values per 
pelvic infection avoided, there is 97–98% probability 
that antibiotic prophylaxis is a cost-effective intervention 
(figure A). In the secondary, worst-case scenario analysis, 
where all censored women were assumed to have pelvic 
infection, antibiotic prophylaxis had 88–89% probability 
of being cost-effective (figure B). The downward slopes of 
Antibiotic prophylaxis 
(n=1660); raw mean 
(SD)
Placebo (n=1680); 
raw mean (SD)
Difference (antibiotic prophylaxis – placebo)
Adjusted mean* Normal-based 
95% CIs†
Normal-based 
95% CIs†
Mean per-woman costs (US$)
Pre-surgery prophylactic antibiotics 0·084 (0·000) 0·000 (0·000) 0·084 ·· ··
Post-surgery antibiotics 0·797 (2·964) 1·068 (3·535) –0·270 –0·490 –0·050
Other medications 0·176 (1·603) 0·212 (2·593) –0·031 –0·179 0·117
Laboratory examinations 0·113 (0·499) 0·154 (0·730) –0·045 –0·086 –0·005
Complications 0·152 (1·678) 0·262 (3·274) –0·121 –0·308 0·066
Hospital services 0·280 (2·452) 0·385 (2·406) –0·112 –0·287 0·063
Total cost (country-specific unit cost estimates) 1·601 (6·419) 2·082 (8·564) –0·496 –1·019 0·026
Total cost (regional unit cost estimates) 2·350 (12·548) 3·040 (14·803) –0·718 –1·693 0·257
Risk of pelvic infection 0·041 (0·198) 0·054 (0·225) –0·013 –0·028 0·002
*Adjusted for age, marital status, gestational age, previous miscarriage or stillbirth, evidence of induced abortion, HIV status, type of miscarriage surgery, surgeon, and 
residential characteristics. †CIs calculated via bias-corrected and accelerated bootstrapping (1000 replications).
Table 3: Mean per-woman costs (US$, 2016 price base) and risk of pelvic infection
Figure: Cost-effectiveness acceptability frontier indicating the probability of 
antibiotic prophylaxis being cost-effective across different willingness-to-pay 
thresholds per pelvic infection avoided in the main (available case) analysis (A) 
and secondary (multiple imputation or worst-case scenario) analysis (B)
The dashed lines show the expected decision maker’s willingness-to-pay for a 
pelvic infection avoided, as estimated from Woods and colleagues35 (blue line) 
and the WHO recommendations (green line).36
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the figure show that decision uncertainty is mainly driven 
by costs rather than outcomes. The conclusions drawn 
from the cost-effectiveness analysis were robust to the 
regional (sensitivity) analysis and all subgroup analyses, 
includ ing the estimation of cost-effectiveness within each 
participating country (appendix p 6).
Discussion
This study assessed the cost-effectiveness of antibiotic 
prophylaxis relative to placebo in women undergoing 
surgical management of miscarriage in low-income 
settings. The findings show that the provision of anti-
biotic prophylaxis before miscarriage surgery results 
in fewer pelvic infections within 2 weeks of surgery 
and lower costs than the current practice of no anti-
biotic prophylaxis. Our analysis concluded that there 
is a 97–98% probability that antibiotic prophylaxis is 
a cost-effective intervention at expected thresholds of 
willingness-to-pay per additional pelvic infection avoided. 
This finding could translate to an annual total cost saving 
of up to $1·4 million if antibiotic prophylaxis was 
used routinely before miscarriage surgery across the 
four participating countries (Malawi, Pakistan, Tanzania, 
and Uganda) and a saving of up to $8·5 million across 
the two regions (sub-Saharan Africa and south Asia; 
appendix p 7).
Antibiotic resistance is a key global threat and reducing 
the unnecessary and inappropriate use of antibiotics is a 
global priority.38 However, we have shown that a single 
prophylactic dose of antibiotics before miscarriage 
surgery is an example of antibiotic usage that is both 
necessary and appropriate, and that it also reduced 
antibiotic usage after surgery.
To the best of our knowledge, this study is the first to 
assess the relative cost-effectiveness of antibiotic prophyl-
axis in the surgical management of miscarriage. The 
study benefited from a large sample size recruited from 
four low-income countries and 13 hospitals, a wide range 
of primary data, and a high follow-up rate. However, the 
study has some limitations. For pragmatic financial, time, 
and trial burden-related reasons, extensive bottom-up 
costing of all resource items was not done during the trial. 
Although this decision probably increased the uncertainty 
around the unit cost estimates used in the analysis, all 
estimates were obtained from valid and reputable sources, 
including the International Drug Price Indicator Guide, 
WHO, and other secondary sources based on thorough 
bottom-up costing. A sen sitivity analysis using regional 
cost estimates led to similar results, which supports the 
generalisability of our findings.
In low-income settings, managing miscarriage 
complica tions can involve substantial out-of-pocket 
expenses,39 such as travel expenses, formal or informal 
expenses for outpatient services and inpatient care, and 
time off work for women and their family members. 
Given the emotionally distressing period after pregnancy 
loss, these expenses were not captured in the trial to 
avoid adding further burden to participants. Nevertheless, 
the increased complication rates seen in the placebo 
group suggest that these costs—in a societal perspective 
of analysis—probably led to an even larger cost difference 
between the two groups. Pelvic infections can also result 
in longer-term effects, such as pelvic pain, ectopic 
pregnancy, and infertility. Cost and disability effects 
associated with these outcomes were not considered in 
the analysis. However, given that pelvic infections 
were more frequent in the placebo group, an exploration 
of these costs and outcomes in a lifetime modelled 
time-horizon would improve the cost-effectiveness of 
antibiotic prophylaxis even further.
Finally, although only 74 (2%) of 3412 women were 
censored at 2 weeks after miscarriage surgery, women in 
the antibiotic prophylaxis group were more likely to be 
missing. This finding could be attributed to the small 
number of women lost to follow-up, or it might indicate 
better effectiveness for antibiotic prophylaxis, but a worst-
case scenario was used for analysis. For this calcula-
tion, costs for censored women were multiply imputed 
assuming the presence of pelvic infection. This analysis 
concluded that, at expected thresholds of willingness-to-
pay per additional pelvic infection avoided, there is 88–89% 
probability that antibiotic prophylaxis is cost-effective.
Current international guidelines recommend the use of 
prophylactic antibiotics in abortion surgery but not in 
miscarriage surgery. Our findings lend strong support 
on the cost-effectiveness of antibiotic prophylaxis before 
miscarriage surgery. Policy makers in various settings 
should be confident that providing prophylactic antibiotics 
in the surgical management of miscarriage is a good use 
of their restricted health-care budgets. Decision making 
guidelines on miscarriage management should be up-
dated to reflect the findings of this study and the efficacy 
evidence from the AIMS trial.
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